8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 9, 2012)

Filed January 9, 2012For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on January 9, 2012, reporting on its key goals for its RNAi therapeutics pipeline in 2012 and providing updated cash guidance for the fiscal year ended December 31, 2011. This filing primarily serves to furnish a press release, which contains the substantive information for investors. The company is focused on advancing its RNA interference (RNAi) therapeutics, a promising area of drug development. Investors should note that this 8-K is a notification of events rather than a comprehensive financial update. The key takeaways will be derived from the attached press release, detailing the company's strategic direction and financial outlook for the upcoming year. The information is being furnished, not filed, under Section 18 of the Exchange Act, meaning it's not subject to the same liability provisions.

Key Highlights

  • 1Alnylam announced its key 2012 goals for its RNAi therapeutics pipeline.
  • 2Updated cash guidance for the year ended December 31, 2011, was provided.
  • 3The press release detailing these announcements was furnished as Exhibit 99.1 to the 8-K.
  • 4The filing date is January 9, 2012, with the earliest event reported on January 8, 2012.
  • 5The report focuses on the company's strategic direction and financial outlook.
  • 6Information furnished via this 8-K is not deemed 'filed' for Section 18 purposes.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and provide access to Alnylam Pharmaceuticals' key 2012 goals for its RNAi therapeutics pipeline and to update its cash guidance for the fiscal year ended December 31, 2011, through an attached press release.

The detailed information is contained within the press release dated January 8, 2012, which is furnished as Exhibit 99.1 to this Form 8-K filing.

When information is 'furnished' under an 8-K, it means the company is providing it to the SEC but it is not subject to the liabilities associated with 'filing' under Section 18 of the Securities Exchange Act of 1934. This is a common distinction for press releases or other announcements that are not part of the company's formal SEC reports like quarterly or annual filings.

The mention of the RNAi therapeutics pipeline highlights Alnylam's focus on a specific and innovative area of drug development. RNAi (RNA interference) is a biological process that silences genes, and its therapeutic application aims to treat diseases by targeting the underlying genetic cause.